Xeris Biopharma Holdings, Inc. (NasdaqGS: XERS)
Health Care · Pharmaceuticals · US
$8.70
+1.16% today · +12.3% 1Y
Xeris Biopharma Holdings, Inc. (NasdaqGS: XERS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.59B and employs 435 people.
Over the last twelve months the share price has gained 12.3%, trading between 5.25 and 10.08.
Tweenvest scores Xeris Biopharma Holdings, Inc. across four factors: quality 36/100, value 35/100, growth 100/100. Its strongest factor is growth.
XERS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.59B
- Revenue (TTM)
- $335.41M
- P/E
- —
- EPS
- -0.10
- Dividend yield
- —
- Beta (5Y)
- 0.85
- 52-week high
- $10.08
- 52-week low
- $5.25
- Avg volume (3M)
- —
- Shares outstanding
- 182.32M
- Employees
- 435
- Next earnings
- —
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
- Founded
- 2005
- Listed since
- Jun 21, 2018
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.